NCT00859560

Brief Summary

The retrospective survey is to investigate the incidence of bone fracture in post-menopausal breast cancer patients with Arimidex 1mg, who were previously registered for the clinical experience investigation.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,205

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2008

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2008

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 10, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 11, 2009

Completed
Last Updated

March 11, 2009

Status Verified

March 1, 2009

First QC Date

March 10, 2009

Last Update Submit

March 10, 2009

Conditions

Breast Cancer

Keywords

Breast cancerpost-menopausal womenArimidexbone fracture

Outcome Measures

Primary Outcomes (1)

  • Bone fracture incidence

    Time since starting Arimidex

Secondary Outcomes (2)

  • Survival

    Time since starting Arimidex

  • Bone density measurement

    Time since starting Arimidex

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Post-menoposal breast cancer patients who were previousely registered in clinical experience investigation with Arimidex 1mg as adjuvant therapy.

You may qualify if:

  • Post-menopausal breast cancer patients treated with Arimidex 1mg at the time of previously conducted clinical experience investigation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Breast NeoplasmsFractures, Bone

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesWounds and Injuries

Study Officials

  • AstraZeneca Japan Medical Director MD

    AstraZeneca

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

March 10, 2009

First Posted

March 11, 2009

Study Start

January 1, 2008

Study Completion

December 1, 2008

Last Updated

March 11, 2009

Record last verified: 2009-03